ESMO 2023: Determining Standard-of-Care Therapy for Medullary Thyroid Carcinoma
Posted: 12/11/2023 | By: Kayci Reyer

In a study presented by Hadoux et al at the European Society for Medical Oncology (ESMO) Congress 2023, investigators compared selpercatinib as first-line therapy with either cabozantinib or vandetanib (control group) in patients with advanced thyroid cancer (Abstract LBA3).

Question 1 of 5

According to research presented at the ESMO Congress 2023, selpercatinib may warrant consideration as first-line treatment for patients with what type of medullary thyroid carcinoma?

Choose 1